Oppenheimer Starts Sierra Oncology Inc (SRRA) at Outperform

December 5, 2019 4:06 PM EST
Get Alerts SRRA Hot Sheet
Price: $16.50 +0.61%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 26 | New: 11
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Oppenheimer analyst Jay Olson initiates coverage on Sierra Oncology Inc (NASDAQ: SRRA) with a Outperform rating and a price target of $1.20.

The analyst comments "We initiate coverage of SRRA with an Outperform rating and $1.20 price target based on what we view as significant commercial potential for the company’s main asset, momelotinib, and our evaluation of its Ph3 registrational clinical trial for myelofibrosis (MF) patients previously treated with a JAK inhibitor. We believe current MF patients who are primarily administered ruxolitinib in 1L often eventually discontinue treatment due to several factors including disease progression and myelosuppression, and new 2L options will be welcomed to address MF symptoms. We view momelotinib as well positioned to secure 2L treatment, given its unique pharmacological properties, prior Ph3 clinical trials and the published literature. Details and analysis inside."

For an analyst ratings summary and ratings history on Sierra Oncology Inc click here. For more ratings news on Sierra Oncology Inc click here.

Shares of Sierra Oncology Inc closed at $0.42 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage